10x Genomics has delivered four consecutive earnings beats with an average positive surprise exceeding 316% and generates 19% free cash flow margins despite GAAP losses, but the stock has exceeded analyst targets by 30% and carries 19% short interest with a put/call ratio of 2.60 and declining revenue.
Thesis pillars
- Fcf Positive Amid Gaap Loss↑Improving
- Massive Earnings Beat Streak↓Deteriorating
- Target Exceeded Sharply↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
10x Genomics, Inc. (TXG) Stock Analysis
Breakout setup
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $56.49, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-supplier components; Analyst target reached - limited upside remaining.
10x Genomics makes instruments, consumables, and software for single-cell and spatial genomic analysis, serving academic, government, biopharmaceutical, and biotechnology institutions across oncology, immunology, and neuroscience. The company generated $642.8 million in revenue... Read more
Hold if already holding. Not a fresh buy at $56.49, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-supplier components; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 4.4/10, moderate confidence.
Passes 8/10 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, news boost analyst cluster(3), earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About 10x Genomics, Inc.
About 10x Genomics, Inc.
10x Genomics generated $642.8 million in revenue in 2025, up 5% from $610.8 million in 2024, with 8,046 cumulative instruments sold to researchers worldwide since launching its first product in mid-2015. During 2025, the company sold 1,007 instruments and 424,000 consumable reactions across its Chromium single-cell, Visium spatial, and Xenium in situ platforms. The 1,178-person workforce as of December 31, 2025 includes 332 in research and development, 473 in sales, marketing and support, and 188 in manufacturing.
Revenue comes from three instrument families plus consumable reagents and proprietary software. The Chromium platform partitions and barcodes individual cells for high-throughput multiomic readouts including gene expression, protein, chromatin, and V(D)J analysis; Visium uses high-density DNA arrays to map transcripts spatially across tissue sections; and Xenium performs in situ RNA detection using circularizable probes and fluorescent hybridization cycles, enabling subcellular spatial resolution without conventional sequencing. Chromium and Visium instruments are outsourced to contract manufacturers maintaining ISO 13485 certification, while Xenium final assembly and optical integration are performed in-house. The majority of consumables are manufactured at facilities in Pleasanton, California, Singapore, and Taiwan. Sales go primarily through a direct salesforce in North America and select regions of Europe, with third-party distributors serving regions of Asia, Europe, and Oceania. Academic and government institutions represent the largest portion of direct sales revenue; no single customer, including distributors, represented greater than 10% of business in 2025. Some components are sourced from a single supplier with no qualified second source, which could cause production delays if that supplier fails.
Show full overview
A substantial portion of 10x Genomics' revenue derives from sales to academic and research institutions relying on NIH grants and other government funding. In March 2025, the NIH terminated approximately 700 research grants totaling more than $2.4 billion covering studies related to breast cancer, Alzheimer's disease, and HIV prevention. A February 2025 NIH policy imposing a standard 15% indirect-cost rate — halted by a federal court injunction in March 2025 and upheld by the First Circuit in January 2026 — remains in an uncertain state, and the company believes delays or cancellations of such funding have caused, and in the future could weigh on, customer purchasing decisions.
See also: Healthcare · Health Information Services
From 10x Genomics, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-08-16Recent Developments — 10x Genomics, Inc.
Latest news
- NEWS 10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - StockStory — StockStory positive
- NEWS Why 10x Genomics Stock Is Surging Today - TipRanks — TipRanks positive
- NEWS 10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance — Yahoo Finance positive
- NEWS 10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates - sharewise.com — sharewise.com positive
- NEWS 10x Genomics (TXG) Q1 2026 Earnings Transcript - The Globe and Mail — The Globe and Mail neutral
Generated 2026-08-16T18:37:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle-supplier components10-K Item 1: 'some of these components are sourced from a single supplier'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $56.49, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-supplier components; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 69, MACD bullish. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $59.48 (+5.3%), stop $52.16 (−8.3%), A.R:R -1.5:1. Score 4.4/10, moderate confidence.
Take-profit target: $59.48 (-23.2% upside). Target $59.48 (+5.3%), stop $52.16 (−8.3%), A.R:R -1.5:1. Stop-loss: $52.16.
Concentration risk — Supplier: single-supplier components; Analyst target reached - limited upside remaining; Weak overall score: 4.4/10.
10x Genomics, Inc. trades at a P/E of N/A (forward 275.9). TrendMatrix value score: 3.1/10. Verdict: Hold.
20 analysts cover TXG with a consensus score of 3.7/5. Average price target: $50.
What does 10x Genomics, Inc. do?10x Genomics makes instruments, consumables, and software for single-cell and spatial genomic analysis, serving...
10x Genomics makes instruments, consumables, and software for single-cell and spatial genomic analysis, serving academic, government, biopharmaceutical, and biotechnology institutions across oncology, immunology, and neuroscience. The company generated $642.8 million in revenue in 2025, selling 1,007 instruments and 424,000 consumable reactions, with 8,046 instruments installed worldwide since launch.